ICR responds to NICE decision about CAR T immunotherapy for non-Hodgkin lymphoma 28 Aug 2018 The ICR responds to draft decision not to recommend CAR T cell therapy for two types of non-Hodgkin lymphoma. Find out more Show/Hide
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer 06 Jun 2018 The Institute of Cancer Research, London, has expressed disappointment that the prostate cancer drug abiraterone (brand name Zytiga) will not be made available to men with advanced prostate cancer as a first-line treatment on the NHS. Find out more Show/Hide
The ICR responds to the FDA approval of olaparib for women with BRCA-mutant advanced breast cancer 12 Jan 2018 The Institute of Cancer Research, London, strongly welcomes the news that olaparib has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer. Find out more Show/Hide
ICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancer 16 Nov 2017